85%Confidence
0Views
FDASource
2026-05-27Date
Summary
A compounding pharmacy error resulted in insulin omission from a TPN bag, posing severe patient safety risks. This may increase regulatory scrutiny on compounding pharmacies and raise liability concerns for CAPS.
Actionable: Monitor CAPS for potential legal actions or operational disruptions; consider reducing exposure to compounding pharmacy stocks.
AI Confidence: 85%
Data Points
firmCentral Admixture Pharmacy Services, Inc (CAPS) Los Angeles
classificationClass II
statusOngoing
distributionCA
productTPN bag (patient specific), Rx# 11-4909703-0-1, Compound Volume 1660 mL per bag, Rx only, Single Dose Injection, Refrigerated Injection, Central Admix
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now